Daptomycin-Oxacillin Combinations in Treatment of Experimental Endocarditis Caused by Daptomycin-Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus with Evolving Oxacillin Susceptibility (the “Seesaw Effect”)
暂无分享,去创建一个
R. Daum | A. Bayer | Y. Xiong | Soo-Jin Yang | T. Jones | S. Boyle‐Vavra
[1] J. Gatell,et al. Daptomycin Is Effective for Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus epidermidis , 2008, Antimicrobial Agents and Chemotherapy.
[2] A. Bayer,et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. , 2009, The Journal of infectious diseases.
[3] K. Ko,et al. Classification of Staphylococcal Cassette Chromosome mec (SCCmec): Guidelines for Reporting Novel SCCmec Elements , 2009, Antimicrobial Agents and Chemotherapy.
[4] J. Miro,et al. Addition of Gentamicin or Rifampin Does Not Enhance the Effectiveness of Daptomycin in Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.
[5] B. Diep,et al. Relationship between Susceptibility to Daptomycin In Vitro and Activity In Vivo in a Rabbit Model of Aortic Valve Endocarditis , 2009, Antimicrobial Agents and Chemotherapy.
[6] V. Fowler,et al. Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. , 2009, The Journal of infectious diseases.
[7] A. Cheung,et al. Role of mgrA and sarA in methicillin-resistant Staphylococcus aureus autolysis and resistance to cell wall-active antibiotics. , 2009, The Journal of infectious diseases.
[8] C. Nast,et al. Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.
[9] N. McCallum,et al. Impact of mecA promoter mutations on mecA expression and beta-lactam resistance levels. , 2008, International journal of medical microbiology : IJMM.
[10] P. Fey,et al. Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. , 2008, Journal of medical microbiology.
[11] J. Miro,et al. Daptomycin Is Effective in Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.
[12] J. Schrenzel,et al. Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding , 2007, Antimicrobial Agents and Chemotherapy.
[13] H. Boucher,et al. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] G. Kaatz,et al. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. , 2007, The Journal of antimicrobial chemotherapy.
[15] A. Rubio,et al. Characterization of a Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Strain in a Patient with Endocarditis , 2007, Antimicrobial Agents and Chemotherapy.
[16] G. Archer,et al. Identification and Phenotypic Characterization of a β-Lactam-Dependent, Methicillin-Resistant Staphylococcus aureus Strain , 2007, Antimicrobial Agents and Chemotherapy.
[17] G. Eliopoulos,et al. Daptomycin Nonsusceptibility in Staphylococcus aureus with Reduced Vancomycin Susceptibility Is Independent of Alterations in MprF , 2007, Antimicrobial Agents and Chemotherapy.
[18] P. Appelbaum,et al. Activity of Daptomycin Alone and in Combination with Rifampin and Gentamicin against Staphylococcus aureus Assessed by Time-Kill Methodology , 2007, Antimicrobial Agents and Chemotherapy.
[19] R. Daum,et al. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton–Valentine leukocidin , 2007, Laboratory Investigation.
[20] A. MacGowan,et al. Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA Isolates , 2006, Antimicrobial Agents and Chemotherapy.
[21] S. Yin,et al. The VraS/VraR two-component regulatory system required for oxacillin resistance in community-acquired methicillin-resistant Staphylococcus aureus. , 2006, FEMS microbiology letters.
[22] G. Archer,et al. Successful Therapy of Experimental Endocarditis Caused by Vancomycin-Resistant Staphylococcus aureus with a Combination of Vancomycin and β-Lactam Antibiotics , 2006, Antimicrobial Agents and Chemotherapy.
[23] Ronald N. Jones,et al. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. , 2006, The Journal of antimicrobial chemotherapy.
[24] L. Friedman,et al. Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.
[25] D. Skiest. Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin , 2006, Journal of Clinical Microbiology.
[26] D. Snydman,et al. Evaluation of In Vitro Interaction of Daptomycin with Gentamicin or Beta-lactam Antibiotics Against taphylococcus aureus and Enterococci by FIC Index and Timed-Kill Curves , 2005, Journal of chemotherapy.
[27] C. Weidenmaier,et al. DltABCD- and MprF-Mediated Cell Envelope Modifications of Staphylococcus aureus Confer Resistance to Platelet Microbicidal Proteins and Contribute to Virulence in a Rabbit Endocarditis Model , 2005, Infection and Immunity.
[28] J. Quinn,et al. Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus , 2005, Journal of Clinical Microbiology.
[29] Chih-Chien Wang,et al. Successful Multiresistant Community-Associated Methicillin-Resistant Staphylococcus aureus Lineage from Taipei, Taiwan, That Carries Either the Novel Staphylococcal Chromosome Cassette mec (SCCmec) Type VT or SCCmec Type IV , 2005, Journal of Clinical Microbiology.
[30] H. de Lencastre,et al. Partial Excision of the Chromosomal Cassette Containing the Methicillin Resistance Determinant Results in Methicillin-Susceptible Staphylococcus aureus , 2005, Journal of Clinical Microbiology.
[31] L. Danziger,et al. Daptomycin: a novel cyclic lipopeptide antimicrobial. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[32] K. Dietz,et al. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. , 2005, The Journal of infectious diseases.
[33] F. Tally,et al. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. , 2005, The Journal of antimicrobial chemotherapy.
[34] A. Tomasz,et al. Penicillin-Binding Protein 2 Is Essential for Expression of High-Level Vancomycin Resistance and Cell Wall Synthesis in Vancomycin- Resistant Staphylococcus aureus Carrying the Enterococcal vanA Gene Complex , 2004, Antimicrobial Agents and Chemotherapy.
[35] M. Rybak,et al. Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model , 2004, Antimicrobial Agents and Chemotherapy.
[36] K. Rand,et al. Synergy of Daptomycin with Oxacillin and Other β-Lactams against Methicillin-Resistant Staphylococcus aureus , 2004, Antimicrobial Agents and Chemotherapy.
[37] H. Mori,et al. Two‐component system VraSR positively modulates the regulation of cell‐wall biosynthesis pathway in Staphylococcus aureus , 2003, Molecular microbiology.
[38] H. Shapiro,et al. Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.
[39] Susan K. Johnson,et al. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] G. Eliopoulos,et al. Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcusaureus , 2003, Antimicrobial Agents and Chemotherapy.
[41] A. Tomasz,et al. Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S. aureus under the Impact of Antibiotics Administered for Chemotherapy , 2003, Journal of Clinical Microbiology.
[42] M. Moore,et al. Vancomycin Treatment Failure Associated with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus in a Patient with Endocarditis and in the Rabbit Model of Endocarditis , 2003, Antimicrobial Agents and Chemotherapy.
[43] G. Bierbaum,et al. Morphological and Genetic Differences in Two Isogenic Staphylococcus aureus Strains with Decreased Susceptibilities to Vancomycin , 2003, Antimicrobial Agents and Chemotherapy.
[44] P. Donnio,et al. Nine-Year Surveillance of Methicillin-Resistant Staphylococcus aureus in a Hospital Suggests Instability of mecA DNA Region in an Epidemic Strain , 2002, Journal of Clinical Microbiology.
[45] R. Daum,et al. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. , 2001, The Journal of antimicrobial chemotherapy.
[46] A. Tomasz,et al. An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] Teruyo Ito,et al. Structural Comparison of Three Types of Staphylococcal Cassette Chromosome mec Integrated in the Chromosome in Methicillin-Resistant Staphylococcus aureus , 2001, Antimicrobial Agents and Chemotherapy.
[48] F. Tally,et al. Development of daptomycin for gram-positive infections. , 2000, Journal of Antimicrobial Chemotherapy.
[49] A. Tomasz,et al. Gradual Alterations in Cell Wall Structure and Metabolism in Vancomycin-Resistant Mutants ofStaphylococcus aureus , 1999, Journal of bacteriology.
[50] G. Archer,et al. Combinations of Vancomycin and β-Lactams Are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin , 1999, Antimicrobial Agents and Chemotherapy.
[51] A. Bayer,et al. Comparative Efficacies of Liposomal Amikacin (MiKasome) plus Oxacillin versus Conventional Amikacin plus Oxacillin in Experimental Endocarditis Induced by Staphylococcus aureus: Microbiological and Echocardiographic Analyses , 1999, Antimicrobial Agents and Chemotherapy.
[52] A. Tomasz,et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. , 1999, The New England journal of medicine.
[53] A. Tomasz,et al. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus , 1997, Journal of bacteriology.
[54] G. Archer,et al. Role of mecA transcriptional regulation in the phenotypic expression of methicillin resistance in Staphylococcus aureus , 1996, Journal of bacteriology.
[55] B. Berger-Bächi. Expression of resistance to methicillin. , 1994, Trends in microbiology.
[56] K. Hiramatsu,et al. Molecular cloning and nucleotide sequence determination of the regulator region of mecA gene in methicillin‐resistant Staphylococcus aureus (MRSA) , 1992, FEBS letters.
[57] A. Bayer,et al. Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci , 1991, Antimicrobial Agents and Chemotherapy.
[58] Lancé,et al. 3-Lactam---Lactamase-Inhibitor Combinations Are Active in Experimental Endocarditis Caused by , B-Lactamase-Producing Oxacillin-Resistant Staphylococci , 2022 .